AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

APYX · NASDAQ · Medical - Specialties

Apyx® Medical

Supplies Renuvion and AYON systems alongside an OEM segment.

$3.12

After-hours close+0.04 (+1.30%)

At close$3.08(+2.67%)

Something off on this page? Send us feedback.

Profile

Apyx Medical CorporationAPYXHealth Care

The Surgical Aesthetics segment sells Renuvion helium-plasma products and the AYON Body Contouring System to cosmetic surgery. An OEM segment complements the business, while J-Plasma serves the hospital surgical market.

Renuvion helium-plasma products and the AYON Body Contouring System form the Surgical Aesthetics segment, which serves the cosmetic-surgery market. AYON integrates fat removal, closed-loop contouring, Renuvion tissue contraction, and electrosurgical capabilities.

Following the sale of its Core business, the company concentrated its advanced-energy business on cosmetic surgery and directs marketing and sales initiatives toward that market. An OEM segment remains alongside Surgical Aesthetics, while J-Plasma is marketed to the hospital surgical market.

Product use and commercial adoption are shaped by FDA-cleared indications. The FDA issued a Safety Communication concerning use of Advanced Energy products outside their cleared indications.

Company facts

CEOCharles D. Goodwin II

ListedJan 2, 2019

ExchangeNASDAQ

HeadquartersClearwater, FL

CountryUnited States

Employees205

CIK0000719135

ISINUS03837C1062

Key statistics

Market cap$129.7M

EPS (ttm)−$0.2067

P/E (ttm)−14.90

ROE-78.7%

P/B12.18

P/S2.22

Dividend yield—

Beta1.31vs XLV 0.09

Year to date −12.0% · Average volume (30d) 131.0K

Analysts

Price target, next 12 months$6.50+111.0%Median of 9 analysts · vs the Aug 28 close

ConsensusBuy8 of 9 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $3.08

High$7.00+127.3%

Median$6.50+111.0%

Low$6.00+94.8%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Target
Jul 13, 2026	H.C. Wainwright	Initiate		Buy	$7
Mar 11, 2026	Craig-Hallum	Reiterate		Buy	$6
Mar 11, 2026	BTIG	Upgrade	Neutral	Buy
Dec 15, 2025	Roth Capital	Target			$6
Nov 12, 2025	Citizens	Upgrade	Market Perform	Market Outperform

Earnings

EPS

Estimate−$0.07

ReportedDue Nov 5, 2026

Revenue

Estimate$13.3M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$0.08	−$0.07	+14.6%	$13.2M	$13.9M	+5.4%	−2.64%
May 7, 2026Q1 FY26	−$0.11	−$0.05	+54.5%	$10.5M	$12.5M	+18.7%	+3.09%
Mar 10, 2026Q4 FY25	−$0.06	−$0.03	+50.0%	$18.5M	$19.2M	+3.4%	+13.91%
Nov 6, 2025Q3 FY25	−$0.06	−$0.05	+16.7%	$18.1M	$12.9M	−28.9%	+15.52%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$9.4M	$11.4M	$12.9M	$19.2M	$12.5M	$13.9M
Gross profit	$5.7M	$7.1M	$8.3M	−$2.0M	$4.7M	$8.9M
Operating income	−$3.1M	−$2.6M	−$832.0K	$11.0K	−$911.0K	−$1.8M
Net income	−$4.2M	−$3.8M	−$2.0M	−$1.3M	−$2.1M	−$3.2M
Diluted EPS	−$0.12	−$0.09	−$0.05	−$0.03	−$0.05	−$0.08
Gross margin	60.1%	62.3%	64.4%	-10.5%	37.4%	63.9%
Operating margin	-32.4%	-22.6%	-6.5%	0.1%	-7.3%	-13.0%

Fiscal years (4-quarter sums)FY21 $48.5M · FY22 $44.5M · FY23 $52.3M · FY24 $48.1M · FY25 $52.8M

Revenue by product · Q2 FY26

OEM$1.5M · 100%

Revenue by geography · Q2 FY26

United States$9.4M · 68%

Non-US$4.5M · 32%

Balance sheet, Jun 30, 2026Cash & short-term investments $27.6M · Total debt $39.6M · Total assets $61.1M · Shareholders' equity $10.7M

Dividends

No dividends on record.

Ownership

Institutions 50.61%21.31M sharesInsiders 1.26%529.3K sharesOther 48.13%20.27M shares

Shares outstanding 42.11M · Float 36.19M · 86.0% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Royce & Associates LP	3.27M	7.77%	13F	Aug 14, 2026
Nantahala Capital Management, LLC	3.27M	7.77%	13F	Aug 19, 2026
Archon Capital Management LLC	2.64M	6.28%	13F	Aug 14, 2026
Vanguard Capital Management LLC	1.53M	3.64%	13F	Aug 13, 2026
Essex Investment Management Co LLC	1.14M	2.70%	13F	Aug 6, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.